PH12019500422A1 - Methods and composition for the prediction of the activity of enzastaurin - Google Patents
Methods and composition for the prediction of the activity of enzastaurinInfo
- Publication number
- PH12019500422A1 PH12019500422A1 PH12019500422A PH12019500422A PH12019500422A1 PH 12019500422 A1 PH12019500422 A1 PH 12019500422A1 PH 12019500422 A PH12019500422 A PH 12019500422A PH 12019500422 A PH12019500422 A PH 12019500422A PH 12019500422 A1 PH12019500422 A1 PH 12019500422A1
- Authority
- PH
- Philippines
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019500422A1 true PH12019500422A1 (en) | 2019-05-27 |
Family
ID=59923555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019500422A PH12019500422A1 (en) | 2016-09-01 | 2019-02-27 | Methods and composition for the prediction of the activity of enzastaurin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (enExample) |
| EP (1) | EP3507384B1 (enExample) |
| JP (3) | JP7197915B2 (enExample) |
| KR (1) | KR20190046935A (enExample) |
| CN (1) | CN109952383B (enExample) |
| AU (1) | AU2017318669B2 (enExample) |
| BR (1) | BR112019003951A2 (enExample) |
| CA (1) | CA3035386A1 (enExample) |
| JO (1) | JOP20190025A1 (enExample) |
| MX (1) | MX2019002377A (enExample) |
| PH (1) | PH12019500422A1 (enExample) |
| RU (1) | RU2019109011A (enExample) |
| SG (2) | SG11201901762WA (enExample) |
| TW (2) | TW202313973A (enExample) |
| WO (1) | WO2018045240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| US20220193062A1 (en) * | 2018-09-12 | 2022-06-23 | Denovo Biopharma Llc | Combination of enzastaurin and inhibitors of btk and uses thereof |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| TWI808838B (zh) * | 2021-07-23 | 2023-07-11 | 高雄醫學大學 | 二代荷爾蒙藥物於治療攝護腺癌療效評估之臨床治療藥物預測暨推薦系統及方法 |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| CN118339312A (zh) * | 2021-11-23 | 2024-07-12 | 索元生物医药(美国)有限公司 | 用于评估多核苷酸递送和癌疗法之功效的组合物和方法 |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
| EP1309679A2 (en) * | 2000-08-16 | 2003-05-14 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| KR102006417B1 (ko) * | 2011-01-31 | 2019-08-01 | 드노보 바이오마커스 인코포레이티드 | 게놈약학적 바이오마커 동정 방법 |
| EP2718486A4 (en) * | 2011-06-08 | 2014-12-31 | Denovo Biopharma Hangzhou Ltd Co | METHODS AND COMPOSITIONS FOR PREDICTING THE ACTIVITY OF A RETINOID RECEPTOR X MODULATOR |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019109011A3 (enExample) | 2021-01-22 |
| AU2017318669A1 (en) | 2019-03-07 |
| MX2019002377A (es) | 2019-09-05 |
| CN109952383B (zh) | 2024-01-05 |
| CN109952383A (zh) | 2019-06-28 |
| JP7197915B2 (ja) | 2022-12-28 |
| BR112019003951A2 (pt) | 2019-06-25 |
| US11421280B2 (en) | 2022-08-23 |
| TW202313973A (zh) | 2023-04-01 |
| SG11201901762WA (en) | 2019-03-28 |
| US20230074781A1 (en) | 2023-03-09 |
| TWI771317B (zh) | 2022-07-21 |
| US20190233902A1 (en) | 2019-08-01 |
| TW201812125A (zh) | 2018-04-01 |
| JP2022173308A (ja) | 2022-11-18 |
| EP3507384B1 (en) | 2023-08-30 |
| JP2019528705A (ja) | 2019-10-17 |
| RU2019109011A (ru) | 2020-10-05 |
| SG10201912134TA (en) | 2020-02-27 |
| KR20190046935A (ko) | 2019-05-07 |
| AU2017318669B2 (en) | 2023-04-20 |
| CA3035386A1 (en) | 2018-03-08 |
| WO2018045240A1 (en) | 2018-03-08 |
| EP3507384A1 (en) | 2019-07-10 |
| JP2020188816A (ja) | 2020-11-26 |
| JOP20190025A1 (ar) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500422A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
| PH12017502153A1 (en) | Diagnostic methods for t cell therapy | |
| CL2019002427A1 (es) | Inhibición de smarca2 para el tratamiento de cáncer. | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2018012492A (es) | Métodos para monitorear y tratar el cáncer. | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
| EA201692477A1 (ru) | Композиции и способы применения для лечения метаболических расстройств | |
| MY193705A (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| MX391815B (es) | AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR). | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| MX2016014306A (es) | Marcadores para terapia con lipoproteinas de alta densidad (hdl). | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
| MA40364A (fr) | Polythérapie pour le traitement du cancer | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions |